Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference

Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP), a clinical-stage biotechnology company, announced it will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference from March 15-17, 2021. The company specializes in developing antiviral therapeutics targeting various viruses, including SARS-CoV-2 and hepatitis C. A pre-recorded webcast of Cocrystal's presentation is available on their website. Interested investors can arrange virtual meetings through Roth Capital Partners or LHA Investor Relations.

BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33^rd Annual Roth Conference being held March 15-17, 2021. A webcast of Cocrystal’s presentation has been pre-recorded and is available on the Company’s website here.

Investors interested in arranging a virtual meeting with Cocrystal management should contact their Roth Capital Partners sales representative or LHA Investor Relations. Roth Conference information is available here.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

# # #

FAQ

When is the Virtual 33rd Annual Roth Conference for Cocrystal Pharma?

The Virtual 33rd Annual Roth Conference for Cocrystal Pharma will take place from March 15-17, 2021.

What is Cocrystal Pharma's focus in biotechnology?

Cocrystal Pharma focuses on developing novel antiviral therapeutics targeting influenza viruses, coronaviruses, hepatitis C viruses, and noroviruses.

How can investors meet Cocrystal Pharma management during the conference?

Investors can arrange virtual meetings with Cocrystal Pharma management by contacting their Roth Capital Partners sales representative or LHA Investor Relations.

Where can I find the webcast of Cocrystal Pharma's presentation?

The pre-recorded webcast of Cocrystal Pharma's presentation is available on the company's official website.

What technologies does Cocrystal Pharma utilize in drug development?

Cocrystal Pharma employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.